The Transcatheter Mitral Valve Implantation (TMVI) system received European CE mark. It is the world first transcatheter mitral valve replacement (TMVR) technology to gain commercial clearance. It addresses a critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option in high-risk surgical patients.
Daily Current Affairs Quiz 2020
This therapy treats significant mitral regurgitation (MR) in patients requiring a heart valve replacement. It provides a safe and effective solution for MR patients who are not candidates for open-heart surgery or transcatheter mitral valve repair.